Neurology Alert – November 1, 2021
November 1, 2021
View Archives Issues
Atogepant, an oral small-molecule inhibitor of the calcitonin gene-related peptide pathway, administered once daily, effectively reduced migraine days in the preventive treatment trial of migraine over a period of 12 weeks.
This study reports data that refutes the U.S. Food and Drug Administration’s class warning regarding suicidality risk in patients with epilepsy who are taking the newer antiepileptics, approved since 2008. The class warning should be reconsidered.
Neurodegenerative Ataxia: Improvement in Motor and Cognitive Outcomes with Cerebello-Spinal Stimulation
Concurrent cerebellar and spinal stimulation with a transcranial direct current stimulation device resulted in improvement of both motor and cognitive functions in patients with several different forms of neurodegenerative ataxia.
This retrospective cohort study of patients with Parkinson’s disease ages 65 years or older residing in Medicare-certified long-term care facilities revealed pimavanserin use vs. nonuse is associated with an increased risk of 30-day hospitalization and higher 90-, 180-, and 365-day mortality.
The diagnosis of thoracic outlet syndrome may be difficult and relies on specific clinical, imaging, vascular, and electrodiagnostic features. None of the currently recommended treatments have been shown to be effective, but there are few randomized clinical treatment trials.